305 related articles for article (PubMed ID: 22409290)
1. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues.
Rutten-van Mölken MP; Goossens LM
Pharmacoeconomics; 2012 Apr; 30(4):271-302. PubMed ID: 22409290
[TBL] [Abstract][Full Text] [Related]
2. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations.
van der Schans S; Goossens LMA; Boland MRS; Kocks JWH; Postma MJ; van Boven JFM; Rutten-van Mölken MPMH
Pharmacoeconomics; 2017 Jan; 35(1):43-63. PubMed ID: 27592021
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
Hertel N; Kotchie RW; Samyshkin Y; Radford M; Humphreys S; Jameson K
Int J Chron Obstruct Pulmon Dis; 2012; 7():183-99. PubMed ID: 22500119
[TBL] [Abstract][Full Text] [Related]
5. An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD.
D'Souza AO; Smith MJ; Miller LA; Kavookjian J
Chest; 2006 Jun; 129(6):1693-708. PubMed ID: 16778291
[TBL] [Abstract][Full Text] [Related]
6. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
Spencer M; Briggs AH; Grossman RF; Rance L
Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
[TBL] [Abstract][Full Text] [Related]
7. A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use.
Price D; Asukai Y; Ananthapavan J; Malcolm B; Radwan A; Keyzor I
Appl Health Econ Health Policy; 2013 Jun; 11(3):259-74. PubMed ID: 23529714
[TBL] [Abstract][Full Text] [Related]
8. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease.
Hogan TJ; Geddes R; Gonzalez ER
Clin Ther; 2003 Jan; 25(1):285-97. PubMed ID: 12637127
[TBL] [Abstract][Full Text] [Related]
9. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.
Dalal AA; Roberts MH; Petersen HV; Blanchette CM; Mapel DW
Int J Chron Obstruct Pulmon Dis; 2010 Dec; 6():13-22. PubMed ID: 21311689
[TBL] [Abstract][Full Text] [Related]
10. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
Ohar JA; Donohue JF
Semin Respir Crit Care Med; 2010 Jun; 31(3):321-33. PubMed ID: 20496301
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
[TBL] [Abstract][Full Text] [Related]
12. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
[TBL] [Abstract][Full Text] [Related]
13. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D
Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients.
Dal NR; Eandi M; Pradelli L; Iannazzo S
Int J Chron Obstruct Pulmon Dis; 2007; 2(2):169-76. PubMed ID: 18044689
[TBL] [Abstract][Full Text] [Related]
15. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
Aaron SD; Vandemheen KL; Fergusson D; Maltais F; Bourbeau J; Goldstein R; Balter M; O'Donnell D; McIvor A; Sharma S; Bishop G; Anthony J; Cowie R; Field S; Hirsch A; Hernandez P; Rivington R; Road J; Hoffstein V; Hodder R; Marciniuk D; McCormack D; Fox G; Cox G; Prins HB; Ford G; Bleskie D; Doucette S; Mayers I; Chapman K; Zamel N; FitzGerald M;
Ann Intern Med; 2007 Apr; 146(8):545-55. PubMed ID: 17310045
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
Price D; Keininger D; Costa-Scharplatz M; Mezzi K; Dimova M; Asukai Y; Ställberg B
Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
[TBL] [Abstract][Full Text] [Related]
17. Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD.
Gao J; Pleasants RA
Int J Chron Obstruct Pulmon Dis; 2015; 10():775-89. PubMed ID: 25926729
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J
Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099
[TBL] [Abstract][Full Text] [Related]
19. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD.
Gani R; Griffin J; Kelly S; Rutten-van Mölken M
Prim Care Respir J; 2010 Mar; 19(1):68-74. PubMed ID: 20094687
[TBL] [Abstract][Full Text] [Related]
20. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
Welsh EJ; Cates CJ; Poole P
Cochrane Database Syst Rev; 2010 May; (5):CD007891. PubMed ID: 20464758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
